TY - JOUR T1 - IDENTIFICATION OF THE RABBIT LIVER UDP-GLUCURONOSYLTRANSFERASE CATALYZING THE GLUCURONIDATION OF 4-ETHOXYPHENYLUREA (DULCIN) JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 1476 LP - 1481 DO - 10.1124/dmd.104.001206 VL - 32 IS - 12 AU - Yoshihiro Uesawa AU - Adam G. Staines AU - Audrey O'Sullivan AU - Kiminori Mohri AU - Brian Burchell Y1 - 2004/12/01 UR - http://dmd.aspetjournals.org/content/32/12/1476.abstract N2 - Dulcin (DL), 4-ethoxyphenylurea, a synthetic chemical about 200 times as sweet as sucrose, has been proposed for use as an artificial sweetener. DL is excreted as a urinary ureido-N-glucuronide after oral administration to rabbits. The phenylurea N-glucuronide is the only ureido conjugate with glucuronic acid known at present; therefore, DL is interesting as a probe to search for new functions of UDP-glucuronosyltransferases (UGTs). Seven UGT isoforms (UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT2B13, UGT2B14, and UGT2B16) have been identified from rabbit liver, but these UGTs have not been investigated using DL as a substrate. In this work, the identities of UGT isoforms catalyzing the formation of DL glucuronide were investigated using rabbit liver microsomes (RabLM) and cloned/expressed as rabbit UGT isoforms. DL-N-glucuronide (DNG) production was determined quantitatively in RabLM and homogenates of COS-7 cells expressing each UGT isoform by using electrospray liquid chromatography-tandem mass spectrometry. Analysis of DNG formation using RabLM, by Eadie-Hofstee plot, gave a Vmax of 0.911 nmol/min/mg protein and the Km of 1.66 mM. DNG formation was catalyzed only by cloned expressed rabbit UGT1A7 and UGT2B16 (Vmax of 3.98 and 1.16 pmol/min/mg protein and a Km of 1.23 and 1.69 mM, respectively). Substrate inhibition of UGT1A7 by octylgallate confirmed the significant contribution of UGT1A7 to the formation of DNG. Octylgallate was further shown to competitively inhibit DNG production by RabLM (Ki = 0.149 mM). These results demonstrate that UGT1A7 is the major isoform catalyzing the N-glucuronidation of DL in RabLM. The American Society for Pharmacology and Experimental Therapeutics ER -